Hillstar Bio Launches with $67M to Develop Precision Immunotherapies for Autoimmune Diseases

Hillstar Bio, a Boston-based biotechnology company, has emerged from stealth mode with a $67 million Series A financing round14.

The company is focused on developing next-generation precision immunology therapies for autoimmune diseases4.

Hillstar Bio's approach selectively targets and depletes pathogenic immune cells while preserving healthy ones, aiming to provide more durable therapeutic responses4.

The lead program targets TRBV9+ T cells and will initially focus on treating axial spondyloarthritis (AxSpA)4.

Investors in the Series A round include Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc Ventures, and Hummingbird Bioscience4.

The funding will support advancing the lead TRBV9 program through clinical proof-of-concept studies, expected to begin in 20264.

Hillstar Bio's leadership team includes CEO Robert Mabry, previously Chief Scientific Officer at Orna Therapeutics8.

The company aims to improve patient outcomes and potentially reduce the long-term need for immunosuppressive therapies in autoimmune conditions4.

Sources:

1. https://www.thepharmaletter.com/hillstar-launches-with-67-million-autoimmune-ambitions

4. https://www.biospace.com/press-releases/hillstar-bio-launches-with-67-million-series-a-financing-to-develop-next-wave-of-precision-immunotherapies-to-transform-autoimmune-treatment

8. https://www.prnewswire.com/news-releases/hillstar-bio-launches-with-67-million-series-a-financing-to-develop-next-wave-of-precision-immunotherapies-to-transform-autoimmune-treatment-302409719.html